Congratulations to our partner Instil Bio, a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, who have recently listed on the Nasdaq under the symbol TIL.
Further details can be found through the links below:
